Physician profile
Matthew James Antony Brink
NPI 1598128829
$158,685.03
in general payments reported to CMS, 2019-2025
35 companies · $47K in 2025
The $47K reported for 2025 was more than what 96% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,452 · 2022: $26K · 2023: $29K · 2024: $55K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Consulting Fee: $40K · Food and Beverage: $14K · Travel and Lodging: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,806.20 |
| Consulting Fee | $39,562.00 |
| Food and Beverage | $13,608.32 |
| Travel and Lodging | $13,466.07 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,837.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $89,106.13 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Research LLC | $23,182.72 | 2022-2025 | Ngenuity |
| Glaukos Corporation | $15,964.21 | 2021-2025 | Idose, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Travoprost Intraocular Implant - Idose |
| Abbvie INC. | $5,979.35 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Alphagan P |
| Alcon Vision LLC | $5,700.47 | 2021-2025 | Simbrinza, Centurion, Wavelight Refractive Suite |
| Bausch & Lomb Americas INC. | $4,674.62 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Dompe US, INC. | $3,633.58 | 2021-2024 | Oxervate |
| New World Medical,INC. | $2,987.93 | 2022-2025 | Streamline, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Allergan, INC. | $1,886.58 | 2021-2022 | |
| Harrow Eye, LLC | $593.78 | 2024-2025 | Iheezo, Vevye |
| Sun Pharmaceutical Industries INC. | $473.68 | 2022-2023 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $422.43 | 2021-2025 | Tecnis Iol |
| Mallinckrodt Hospital Products INC. | $420.61 | 2022-2025 | Acthar |
| Nova Eye, INC. | $406.45 | 2024-2025 | |
| Rayner Intraocular Lenses Limited | $394.65 | 2022-2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Brink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.